Browse CCL20

Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Acts as a ligand for C-C chemokine receptor CCR6. Signals through binding and activation of CCR6 and induces a strong chemotactic response and mobilization of intracellular calcium ions (PubMed:11352563, PubMed:11035086, PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is responsible for the chemotaxis of dendritic cells (DC), effector/memory T-cells and B-cells and plays an important role at skin and mucosal surfaces under homeostatic and inflammatory conditions, as well as in pathology, including cancer and various autoimmune diseases (PubMed:21376174). CCL20 acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes (PubMed:9038201, PubMed:11352563). Involved in the recruitment of both the proinflammatory IL17 producing helper T-cells (Th17) and the regulatory T-cells (Treg) to sites of inflammation. Required for optimal migration of thymic natural regulatory T cells (nTregs) and DN1 early thymocyte progenitor cells (By similarity). C-terminal processed forms have been shown to be equally chemotactically active for leukocytes (PubMed:11035086). Positively regulates sperm motility and chemotaxis via its binding to CCR6 which triggers Ca2+ mobilization in the sperm which is important for its motility (PubMed:23765988, PubMed:25122636). Inhibits proliferation of myeloid progenitors in colony formation assays (PubMed:9129037). May be involved in formation and function of the mucosal lymphoid tissues by attracting lymphocytes and dendritic cells towards epithelial cells (By similarity). Possesses antibacterial activity towards E.coli ATCC 25922 and S.aureus ATCC 29213 (PubMed:12149255).

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002548 monocyte chemotaxis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032496 response to lipopolysaccharide
GO:0032610 interleukin-1 alpha production
GO:0032612 interleukin-1 production
GO:0032650 regulation of interleukin-1 alpha production
GO:0032652 regulation of interleukin-1 production
GO:0032730 positive regulation of interleukin-1 alpha production
GO:0032732 positive regulation of interleukin-1 production
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035584 calcium-mediated signaling using intracellular calcium source
GO:0040017 positive regulation of locomotion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042222 interleukin-1 biosynthetic process
GO:0042742 defense response to bacterium
GO:0043410 positive regulation of MAPK cascade
GO:0045360 regulation of interleukin-1 biosynthetic process
GO:0045362 positive regulation of interleukin-1 biosynthetic process
GO:0048247 lymphocyte chemotaxis
GO:0050719 interleukin-1 alpha biosynthetic process
GO:0050721 regulation of interleukin-1 alpha biosynthetic process
GO:0050726 positive regulation of interleukin-1 alpha biosynthetic process
GO:0050900 leukocyte migration
GO:0051272 positive regulation of cellular component movement
GO:0051767 nitric-oxide synthase biosynthetic process
GO:0051769 regulation of nitric-oxide synthase biosynthetic process
GO:0051770 positive regulation of nitric-oxide synthase biosynthetic process
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070391 response to lipoteichoic acid
GO:0070555 response to interleukin-1
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071223 cellular response to lipoteichoic acid
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0072679 thymocyte migration
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0098542 defense response to other organism
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0031731 CCR6 chemokine receptor binding
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL20 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCL20 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26719303Colorectal CarcinomaPromote immunity (infiltration)Indeed, owing to IL-17 secretion, CRC-derived Th17 triggered the release of protumorigenic factors by tumour and tumour-associated stroma. However, on the other hand, they favoured recruitment of beneficial neutrophils through IL-8 secretion and, most importantly, they drove highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour tissue, through CCL5 and CCL20 release.
26837767Hepatocellular CarcinomaInhibit immunity (T cell function)Collectively, our findings suggest that the HIF-1α/CCL20/IDO axis in hepatocellular carcinoma is important for accelerating tumor metastasis through both the induction of EMT and the establishment of an immunosuppressive tumor microenvironment, warranting further investigation into the therapeutic effects of blocking specific nodes of this signaling network.
25505237Nasopharyngeal CarcinomaInhibit immunity (T cell function)CCL20 allowed the intratumoral recruitment of human Treg.
16709808MelanomaPromote immunityOur studies suggest that CCL20 processing in the extracellular environment of melanoma cells is exclusively mediated by cathepsin D. Thus, we propose a model where cathepsin D inactivates CCL20 and possibly prevents the establishment of an effective antitumoral immune response in melanomas.
27530322GlioblastomaInhibit immunity (T cell function)CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Here we report that macrophages and microglia within the glioma microenvironment produce CCL2, a chemokine that is critical for recruiting both CCR4+?Treg and CCR2+Ly-6C+?monocytic MDSCs in this disease setting. In murine gliomas, we established novel roles for tumor-derived CCL20 and osteoprotegerin in inducing CCL2 production from macrophages and microglia.
18684866Hodgkin LymphomaInhibit immunity (T cell function)Furthermore, IL-21 is involved in up-regulation of the CC chemokine macrophage-inflammatory protein-3alpha (MIP-3alpha) in HRS cells. MIP-3alpha in turn attracts CCR6(+)CD4(+)CD25(+)FoxP3(+)CD127(lo) regulatory T cells toward HRS cells, which might favor their immune escape.
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL20 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL20 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1750.793
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2290.841
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1240.905
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.3280.165
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.9340.0355
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7240.633
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9980.212
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.250.829
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.9370.118
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6820.738
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3780.623
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2430.455
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCL20 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL20. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL20. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL20.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL20. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL20 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL20 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL20
Namechemokine (C-C motif) ligand 20
Aliases LARC; MIP-3a; exodus-1; ST38; CKb4; SCYA20; small inducible cytokine subfamily A (Cys-Cys), member 20; Exodu ......
Chromosomal Location2q36.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL20 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.